Progress ReportThe ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudyof InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useoftumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease

Mario Cottone, Livia Biancone, Anna Kohn, Fernando Rizzello, Claudio Papi, Alessandro Armuzzi, Gilberto Poggioli, Aurora Bortoli, Renata D'Incà, Fabiana Castiglione, Sandro Ardizzone, Paolo Gionchetti, Vito Annese, Maurizio Vecchi

Risultato della ricerca: Article

107 Citazioni (Scopus)

Abstract

Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon-sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse.Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisationhave publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces-sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.ForthesereasonstheItalian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDiseasehave decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease.The followingitemshavebeenchosen:definitionsofactive,inactive,steroiddependentandresistantdisease; measuresofactivity;anti-tumornecrosisfactoralphatherapyuseinactivesteroiddependentand refractoryluminalCrohn’sDisease,infistulisingCrohn’sDisease,insteroiddependentandresistantactive UlcerativeColitis;riskofcancer;riskofinfectionsduringanti-tumornecrosisfactoralphatherapy;special situations.Theseguidelinesarebasedonevidencefromrelevantmedicalliteratureandclinicalexperience ofanationalworkinggroup.
Lingua originaleEnglish
pagine (da-a)1-20
Numero di pagine21
RivistaDigestive and Liver Disease
Volume43
Stato di pubblicazionePublished - 2011

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cita questo

Progress ReportThe ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudyof InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useoftumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease. / Cottone, Mario; Biancone, Livia; Kohn, Anna; Rizzello, Fernando; Papi, Claudio; Armuzzi, Alessandro; Poggioli, Gilberto; Bortoli, Aurora; D'Incà, Renata; Castiglione, Fabiana; Ardizzone, Sandro; Gionchetti, Paolo; Annese, Vito; Vecchi, Maurizio.

In: Digestive and Liver Disease, Vol. 43, 2011, pag. 1-20.

Risultato della ricerca: Article

Cottone, M, Biancone, L, Kohn, A, Rizzello, F, Papi, C, Armuzzi, A, Poggioli, G, Bortoli, A, D'Incà, R, Castiglione, F, Ardizzone, S, Gionchetti, P, Annese, V & Vecchi, M 2011, 'Progress ReportThe ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudyof InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useoftumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease', Digestive and Liver Disease, vol. 43, pagg. 1-20.
Cottone, Mario ; Biancone, Livia ; Kohn, Anna ; Rizzello, Fernando ; Papi, Claudio ; Armuzzi, Alessandro ; Poggioli, Gilberto ; Bortoli, Aurora ; D'Incà, Renata ; Castiglione, Fabiana ; Ardizzone, Sandro ; Gionchetti, Paolo ; Annese, Vito ; Vecchi, Maurizio. / Progress ReportThe ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudyof InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useoftumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease. In: Digestive and Liver Disease. 2011 ; Vol. 43. pagg. 1-20.
@article{70e9c0fa45d94f0b9f00ddd3a1d5b87a,
title = "Progress ReportThe ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudyof InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useoftumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease",
abstract = "Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon-sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse.Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisationhave publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces-sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.ForthesereasonstheItalian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDiseasehave decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease.The followingitemshavebeenchosen:definitionsofactive,inactive,steroiddependentandresistantdisease; measuresofactivity;anti-tumornecrosisfactoralphatherapyuseinactivesteroiddependentand refractoryluminalCrohn’sDisease,infistulisingCrohn’sDisease,insteroiddependentandresistantactive UlcerativeColitis;riskofcancer;riskofinfectionsduringanti-tumornecrosisfactoralphatherapy;special situations.Theseguidelinesarebasedonevidencefromrelevantmedicalliteratureandclinicalexperience ofanationalworkinggroup.",
keywords = "Guidelines.Biologics.Inflammatory bowel disease.",
author = "Mario Cottone and Livia Biancone and Anna Kohn and Fernando Rizzello and Claudio Papi and Alessandro Armuzzi and Gilberto Poggioli and Aurora Bortoli and Renata D'Inc{\`a} and Fabiana Castiglione and Sandro Ardizzone and Paolo Gionchetti and Vito Annese and Maurizio Vecchi",
year = "2011",
language = "English",
volume = "43",
pages = "1--20",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",

}

TY - JOUR

T1 - Progress ReportThe ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudyof InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useoftumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease

AU - Cottone, Mario

AU - Biancone, Livia

AU - Kohn, Anna

AU - Rizzello, Fernando

AU - Papi, Claudio

AU - Armuzzi, Alessandro

AU - Poggioli, Gilberto

AU - Bortoli, Aurora

AU - D'Incà, Renata

AU - Castiglione, Fabiana

AU - Ardizzone, Sandro

AU - Gionchetti, Paolo

AU - Annese, Vito

AU - Vecchi, Maurizio

PY - 2011

Y1 - 2011

N2 - Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon-sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse.Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisationhave publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces-sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.ForthesereasonstheItalian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDiseasehave decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease.The followingitemshavebeenchosen:definitionsofactive,inactive,steroiddependentandresistantdisease; measuresofactivity;anti-tumornecrosisfactoralphatherapyuseinactivesteroiddependentand refractoryluminalCrohn’sDisease,infistulisingCrohn’sDisease,insteroiddependentandresistantactive UlcerativeColitis;riskofcancer;riskofinfectionsduringanti-tumornecrosisfactoralphatherapy;special situations.Theseguidelinesarebasedonevidencefromrelevantmedicalliteratureandclinicalexperience ofanationalworkinggroup.

AB - Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon-sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse.Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisationhave publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces-sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.ForthesereasonstheItalian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDiseasehave decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease.The followingitemshavebeenchosen:definitionsofactive,inactive,steroiddependentandresistantdisease; measuresofactivity;anti-tumornecrosisfactoralphatherapyuseinactivesteroiddependentand refractoryluminalCrohn’sDisease,infistulisingCrohn’sDisease,insteroiddependentandresistantactive UlcerativeColitis;riskofcancer;riskofinfectionsduringanti-tumornecrosisfactoralphatherapy;special situations.Theseguidelinesarebasedonevidencefromrelevantmedicalliteratureandclinicalexperience ofanationalworkinggroup.

KW - Guidelines.Biologics.Inflammatory bowel disease.

UR - http://hdl.handle.net/10447/53766

M3 - Article

VL - 43

SP - 1

EP - 20

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

ER -